文献速递肺外科

立体定向放疗与手术治疗非小细胞肺癌的系统综述与荟萃分析

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-09-15

该系统综述与荟萃分析比较了立体定向体部放疗(SBRT)与手术在高危早期非小细胞肺癌患者中的疗效。结果显示手术在未匹配和匹配队列中均与更优的总生存相关,且癌症特异性生存、无病生存和无局部区域复发均优于SBRT;但SBRT围手术期死亡更少。

要点

  • 手术在匹配和未匹配队列中均显示总生存优于SBRT。
  • 肺叶切除和亚肺叶切除的总生存均优于SBRT。
  • SBRT围手术期死亡少于手术。

核心结论

  • 当前证据表明手术在中长期临床结局方面优于SBRT,但SBRT围手术期死亡率更低。
  • 手术结局改善可能至少部分归因于基线特征不平衡。

研究设计与样本

  • 系统综述与荟萃分析,通过在线数据库按预设标准检索相关研究。

主要发现

  • 未匹配队列中手术与更优总生存相关(OR 2.49;95%CI 2.10-2.94;P < .00001)。
  • 匹配队列中手术与更优总生存相关(OR 1.71;95%CI 1.52-1.93;P < .00001)。
  • 亚组分析显示肺叶切除和亚肺叶切除的总生存均优于SBRT。
  • 未匹配和匹配队列中,手术的癌症特异性生存、无病生存和无局部区域复发均更优。
  • SBRT与更少的围手术期死亡相关。

临床怎么用

  • 对于可手术的高危早期非小细胞肺癌患者,手术可能提供更优的中长期生存。
  • SBRT可作为围手术期死亡风险较高患者的替代选择。

局限性

  • 手术结局改善可能至少部分由基线特征不平衡导致。
  • 未来研究应提供恶性肿瘤的组织病理学确认,并比较SBRT与微创解剖性切除。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Stereotactic body radiation therapy is the preferred treatment modality for patients with inoperable early-stage non-small cell lung cancer. However, comparative outcomes between stereotactic body radiation therapy and surgery for high-risk patients remain controversial. The primary aim of the present meta-analysis was to assess overall survival in matched and unmatched patient cohorts undergoing stereotactic body radiation therapy or surgery. Secondary end points included cancer-specific survival, disease-free survival, disease recurrence, and perioperative outcomes. METHODS: A systematic review of relevant studies was performed through online databases using predefined criteria. The most updated studies were selected for meta-analysis according to unmatched and matched patient cohorts. RESULTS: Thirty-two studies were identified in the systematic review, and 23 were selected for quantitative analysis. Surgery was associated with superior overall survival in both unmatched (odds ratio, 2.49; 95% confidence interval, 2.10-2.94; P < .00001) and matched (odds ratio, 1.71; 95% confidence interval, 1.52-1.93; P < .00001) cohorts. Subgroup analysis demonstrated superior overall survival for lobectomy and sublobar resection compared with stereotactic body radiation therapy. In unmatched and matched cohorts, cancer-specific survival, disease-free survival, and freedom from locoregional recurrence were superior after surgery. However, stereotactic body radiation therapy was associated with fewer perioperative deaths. CONCLUSIONS: The current evidence suggests surgery is superior to stereotactic body radiation therapy in terms of mid- and long-term clinical outcomes; stereotactic body radiation therapy is associated with lower perioperative mortality. However, the improved outcomes after surgery may be due at least in part to an imbalance of baseline characteristics. Future studies should aim to provide histopathologic confirmation of malignancy and compare stereotactic body radiation therapy with minimally invasive anatomical resections.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Cao C, Wang D, Chung C, et al. A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2018. PMID: 30482524. doi:10.1016/j.jtcvs.2018.08.075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。